Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
Launch financing of $300M enables Beeline to operationalize an in-licensed immunology portfolio, with afimetoran (TLR7/8) in ...
A reverse-merger structure uses Galera’s public listing and cash to bring Obsidian public, while Madan Jagasia is slated to ...
Copay programs now directly influence access and manufacturer financial performance amid high deductibles, ...
While FDA’s draft guidance may alleviate some of the pressures when biosimilar developers, there are still other significant ...
Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, notes select ...
In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical ...
Exclusive global rights (excluding mainland China, Hong Kong, and Macau) position AbbVie to integrate Haisco’s early-stage ...
Full FDA approval establishes sparsentan as the first approved therapy for FSGS, addressing a longstanding reliance on ...
Thomas Newcomer is senior vice president and head of US commercial Samsung Bioepis. The IRA and MFN are affecting decisions made all throughout the entire drug development process.
The guidance proposed the elimination of certain PK studies, including PK studies comparing the biosimilar to a US licensed ...
Deepak Prakash, VP of healthcare at Identiv, spoke with Pharmaceutical Executive, about how all of this is impacting clinical ...
Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, touched on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results